Previous close | 69.72 |
Open | 69.78 |
Bid | 69.10 x 100 |
Ask | 69.31 x 200 |
Day's range | 68.14 - 70.00 |
52-week range | 45.50 - 76.11 |
Volume | |
Avg. volume | 793,518 |
Market cap | 6.699B |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.46 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 83.77 |
Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company
Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold 61,277 shares of the company on March 11, 2024, according to a recent SEC Filing.